ExeVir Bio secures EUR 25 million venture debt financing from European Investment Bank

Ghent, Belgium, 9 Jan 2023: ExeVir Bio, a biotech company developing robust nanobody therapies for broad protection against infectious diseases, today announced that it has secured a venture debt financing agreement of up to EUR 25M (around USD 26.5m) with the European Investment Bank (EIB)*. The EIB financing will help advance ExeVir’s lead asset, XVR012, into clinical trials for COVID-19.

Read full release.